Auxilium Pharmaceuticals up Nearly 9% on Positive Top-Line Results
Auxilium Pharmaceuticals (NASDAQ: AUXL) is trading higher on the session following positive top-line phase 3 results. In IMPRESS I at 52 weeks, the co-primary endpoints met statistical significance with a 37.6% mean reduction in penile curvature deformity for XIAFLEX subjects.
Adrian Adams, Auxilium's Chief Executive Officer and President stated: "We believe that XIAFLEX, if approved for the treatment of Peyronie's Disease, has the clinical profile to become a potential breakthrough procedure. With its current indication in Dupuytren's contracture, positive topline clinical results in Peyronie's Disease, and development ongoing in Frozen Shoulder syndrome and cellulite, XIAFLEX represents a pipeline in a product with potential applications in multiple therapeutic areas that currently have limited options."
Auxilium Pharmaceuticals is currently trading at $20.48, a gain of $1.63 or 8.65%.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.